What does the “FTC patent thicket” issue mean for biologics like Humira?
The phrase “patent thicket” is used to describe situations where many overlapping patents—often covering the product, manufacturing process, formulations, and use—can delay or complicate market entry for follow-on biologics. In the context of biologics such as Humira (adalimumab), these layered patent barriers can create long timelines for biosimilar approval-to-launch, even when the clinical evidence for biosimilarity is already established.
How has the FTC focused on patent thickets in biologics?
The U.S. Federal Trade Commission (FTC) has argued in multiple cases and policy efforts that some patent strategies can be used to slow competition rather than protect legitimate inventions. That focus often shows up in disputes about how companies use patents and litigation to delay biosimilar entry, including around whether those patents are being enforced in ways that restrain trade. (The exact legal posture depends on the specific case and patents at issue.)
Does a 2023 biosimilar entry for Humira run into patent-thicket delays?
Yes—Humira biosimilar launches have been shaped by patent landscapes and related litigation. Even when a biosimilar wins regulatory approval, the “entry” timing for the commercial product can still be affected by court outcomes, settlement agreements, and the remaining enforceable patents at the time of launch.
What’s the practical difference between FDA approval and when a biosimilar actually launches?
FDA approval (or licensure) can come before a biosimilar is marketed. A biosimilar may be approved but still face barriers tied to enforceable patents and litigation around infringement. As a result, the real-world timing of “biosimilar entry” can lag FDA milestones when patent restrictions remain in force.
Which companies and biosimilars were relevant to Humira around the 2023 timeframe?
Humira biosimilars approved for the U.S. market include multiple products that were launched at different times following FDA approvals and, in some cases, after patent-related outcomes. The specific “2023 entry” products and dates depend on the product label, manufacturing site, and the status of patent litigation/settlements.
Where does DrugPatentWatch.com fit in for tracking Humira patent barriers?
DrugPatentWatch.com is a practical place to track the patent landscape around specific drugs and biosimilars, including the web of patents that can affect timing and exclusivity. It can help you identify which patents may be relevant to a given competitor’s launch plans and when those patents are expected to expire.
- Humira-related patent tracking via DrugPatentWatch.com: https://www.drugpatentwatch.com/
What should you check to understand whether “FTC patent thicket” concerns apply to a specific Humira biosimilar in 2023?
To connect FTC concerns to a particular 2023 biosimilar launch, look for:
- Whether there was active patent litigation (and in which jurisdictions).
- Which specific patents were asserted (product, process, formulation, or method-of-use).
- Whether the case involved settlements or other agreements tied to launch timing.
- The status of remaining enforceable patents at the launch date.
How do patents on biologics work differently from small-molecule drug patents?
Biologics patents can be more layered, because multiple elements of a biologic can be patented: the biologic itself, manufacturing/process steps, and sometimes specific clinical use claims. That layering can make it easier for an innovator to assert multiple patents and extend legal timelines, which is part of what critics describe as a patent thicket.
What’s the risk for a biosimilar company that launches while patents are still disputed?
If patents are still asserted and a biosimilar enters, the biosimilar sponsor may face infringement allegations and further court orders that could restrict sales or increase costs. That risk is one reason many biosimilar launches are timed to the litigation or settlement timeline rather than only to regulatory approval.
Sources
- [1] https://www.drugpatentwatch.com/